CDCM 6th Annual Symposium

Lloyd Minor, MD, Dean, School of Medicine, Stanford University

David Entwistle, President and CEO, Stanford Health Care

Paul King, President and CEO, Stanford Children's Health

Maria Grazia Roncarolo, MD, Director, CDCM, Stanford University

Introduction of Keynote: Maria Grazia Roncarolo

Keynote: Marina Cavazzana, MD, Director of Biotherapy Department - Hôpital Necker Enfants Malades - Paris - France

"Gene Therapy for Inherited Disease of the Hemapoietic System Between Safety and Efficacy"

Session 1             Highlights of Stem and Gene Therapy at Stanford

                                 Moderator: Tony Oro

Lay Teng Ang, PhD, Siebel Investigator, Institute for Stem Cell Biology & Regenerative Medicine

"A Stem Cell-Based Toolkit to Study Deadly Biosafety Level 4 Viruses"

Sriram Vaidyanathan, PhD, Instructor, Department of Pediatrics, Stanford University

"Development of an Autologous Genome Edited Airway Stem Cell Therapy for Cystic Fibrosis Sinus Disease"

Session 2             Product Development and Regulatory Framework

                                 Moderator: Steve Feldman

Isabelle Rivière, PhD, Director, Cell Therapy & Cell Engineering Facility, Memorial Sloan Kettering Cancer Center

Neehar Bhatia Memorial Lecture - "CAR T Cell Manufacturing in the Academic Setting"

David DiGiusto, PhD, Chief Technology Officer, Cell and Gene Therapy, National Resilience, Inc and Founding Director, Stanford Laboratory for Cell and Gene Medicine

"Challenges and Successes of Process Development and Manufacturing in Cell and Gene Therapy"

Jessica Chery, PhD, CMC Reviewer, Gene and Cell Therapy Branch, FDA

"Considerations for Development of Gene and Cell Therapy Products"

Lunch Break: "Q&A with the CDCM Experts" (individual Zoom sessions)

Mrinmoy Nag, PhD: Director of Quality Control, Laboratory for Cell and Gene Medicine, Stanford University – Quality in the GMP Setting

Sunita Rajdev, PhD: Senior Associate Director, Strategic Alliances, Office of Technology Licensing, Stanford University – Technology Licensing (will be joined by patent attorney Joe C. Hao, PhD, Kilpatrick Townsend & Stockton LLP)

Ali Bouge, MS, RAC: Director, Regulatory Affairs and Quality Assurance, Stem Cell and Gene Therapy Clinical Trials Program, Stanford University – Regulatory Management of Clinical Trials

Chaitan Khosla, PhD: Professor of Chemistry, and Director, Innovative Medicines Accelerator, Stanford University – Advancing Discoveries

Session 3             Clinical Applications and Impact on Patients

                                 Moderator: Fraser Wright

Glenn Pierce, MD, PHD, Vice President, Medical, World Federation of Hemophilia

"Scientific, Medical, and Patient Perceptions of AAV Gene Therapies"

Crystal Mackall, MD, Ernest and Amelia Gallo Family Professor of Pediatrics and Medicine; Founding Director, Stanford Center for Cancer Cell Therapy

"CAR T Cells for Diffuse Midline Gliomas"

Ravi Majeti MD, PhD, Professory of Medicine; Chief, Division of Hematology, Stanford University

"Reprogramming B-ALL into Antigen Presenting Cells for Cancer Vaccination"

Introduction of Keynote: Matthew Porteus, MD, PhD, Co-Director, CDCM, Stanford University

Keynote: Irv Weissman, MD, Director, Institute of Stem Cell Biology and Regenerative Medicine, Stanford University

"Translating Stem Cell Biology into Regenerative Medicine: More Barriers Than Accelerators"